Thermo Fisher Scientific launches new research assay for cancer

Thermo Fisher Scientific has launched a new targeted next-generation sequencing research panel for the analysis of cancer-relevant genes.

The Ion Torrent Oncomine Myeloid Research Assay is designed for the analysis of DNA mutations, RNA fusion transcripts and gene expression levels associated with myeloid cancers.

It is able to simultaneously cover 74 genes in a single run, yielding results in two or three days, and can aid the study of myeloid leukaemia, myeloid dysplastic syndrome and myeloproliferative neoplasm, among other conditions.

The assay's workflow is optimised for the Ion Chef System for library preparation, which reduces total hands-on time to less than 45 minutes. It offers efficiency gains compared to current approaches for analysing haematological disorders, which often require multiple analyses using different technologies, increasing costs and causing delays.

Andy Felton, vice-president for clinical sequencing product management at Thermo Fisher, said: "The addition of the Oncomine Myeloid Research Assay now provides clinical researchers with yet another tool that will help drive their understanding of blood-based cancers and enable development of potential strategies for future application in precision medicine."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.